Russell M. Medford

DR. RUSSELL M. MEDFORD is Scientific co-Founder, President and Chief
Executive Officer of AtheroGenics, Inc., an Atlanta-based pharmaceutical
company focused on the discovery, development and commercialization of
novel drugs for the treatment of chronic inflammatory diseases. He has
served as a member of AtheroGenics’ Board of Directors since the
company’s inception in 1993. Dr. Medford has been the President and
Chief Executive Officer since 1995 after serving as Executive Vice
President from 1993 to 1995. Dr. Medford is the Director of privately
held Inhibitex, Inc. He is an inaugural Fellow of the Council on Basic
Cardiovascular Sciences of the American Heart Association and a past
Advisory Committee member to the National Heart, Lung and Blood
Institute of the National Institutes of Health. Dr. Medford serves as
Vice Chairman on the Georgia BioMedical Partnership Board of Directors
and is a member of the BioSciences Executive Committee for the Metro
Atlanta Chamber of Commerce. He is also Chair of the National Committee
of the Georgia Life Sciences 2003 and serves on the SELSA (Southeastern
Life Sciences Association) Board of Directors. Since 1989, Dr. Medford
has held a number of academic appointments at the Emory University
School of Medicine, recently as an Associate Professor of Medicine and
Director of Molecular Cardiology, and is currently Clinical Professor
(adjunct) of Medicine. Dr. Medford is a molecular cardiologist whose
research has focused on the molecular basis of cardiovascular disease.
He has published widely in the field of molecular cardiology and holds
11 US patents. Dr. Medford received a BA from Cornell University, and an
MD with distinction and a PhD in Molecular and Cell Biology from the
Albert Einstein College of Medicine. Dr. Medford completed his residency
in internal medicine at the Beth Israel Hospital and his fellowship in
cardiology at the Brigham and Women’s Hospital and Harvard Medical
School, where he also served on the faculty of Medicine.